Drug Price Trends for AZILECT

Average Pharmacy Cost for AZILECT

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
AZILECT 0.5 MG TABLET	68546-0142-56	44.04633	EACH	2026-01-01
AZILECT 1 MG TABLET	68546-0229-56	44.08043	EACH	2026-01-01

Azilect Market Analysis and Price Projections

Last updated: February 19, 2026

Azilect (rasagiline), an irreversible monoamine oxidase-B (MAO-B) inhibitor, is prescribed for the treatment of Parkinson's disease. The drug's market performance is influenced by patent expiries, generic competition, clinical efficacy, and patient access. This analysis examines current market dynamics and projects future price trends.

What is the Current Market Landscape for Azilect?

Azilect is approved for both monotherapy in early-stage Parkinson's disease and as an adjunct therapy in later stages when levodopa treatment is experiencing motor fluctuations.

Approved Indications and Dosage Forms

• Monotherapy: Treatment of signs and symptoms of Parkinson's disease.
• Adjunct Therapy: In combination with levodopa/carbidopa for patients experiencing motor fluctuations.
• Dosage: Available in 0.5 mg and 1 mg oral tablets.

Key Market Players and Competition

Teva Pharmaceutical Industries developed Azilect. The primary competitive pressure stems from the expiry of its key patents, leading to the introduction of generic versions.

• Innovator: Teva Pharmaceutical Industries (brand name Azilect).
• Generics: Multiple pharmaceutical companies have launched generic rasagiline mesylate products following patent expirations. Major generic manufacturers include Mylan (now Viatris), Dr. Reddy's Laboratories, and Accord Healthcare.
• Alternative Therapies: The Parkinson's disease market includes other drug classes such as dopamine agonists (e.g., pramipexole, ropinirole), carbidopa/levodopa formulations, and other MAO-B inhibitors (e.g., selegiline, safinamide).

Patent Expirations and Generic Entry

The U.S. patent for Azilect expired in 2016, and key formulation patents expired later. This allowed for the rapid entry of generic competition in the United States. In Europe, patent expiries varied by country but generally occurred between 2015 and 2017.

• U.S. Patent Expiry: 2016 (for the primary composition of matter patent).
• European Patent Landscape: Expiries varied by jurisdiction; generic entry commenced around 2015-2017 in major European markets.

This patent expiry timeline is a critical factor in the current market pricing and availability of rasagiline.

How Has Generic Competition Impacted Azilect Pricing?

The introduction of generic rasagiline has significantly altered the pricing structure for the drug.

Price Erosion Trends

Following generic entry, brand-name Azilect prices have experienced substantial erosion due to increased competition. Generic manufacturers typically offer products at significantly lower price points to gain market share.

• Average Wholesale Price (AWP) Decline: Post-generic entry, the AWP for rasagiline mesylate has decreased by an estimated 60-80% compared to brand-name Azilect in the U.S. market. Specific price reductions vary based on contract negotiations with payers and pharmacy benefit managers.
• List Price vs. Net Price: While list prices of branded Azilect may remain, the actual net price paid by payers and patients is considerably lower due to rebates and discounts offered by Teva to maintain some market share. Generic prices are more directly reflective of manufacturing costs and competitive market dynamics.

Impact on Market Share

Teva's market share for rasagiline has diminished considerably with the availability of multiple generic alternatives. Prescriptions increasingly favor the lower-cost generic options.

• Generic Prescribing Rate: In major markets like the U.S. and Europe, generic rasagiline accounts for over 90% of total rasagiline prescriptions.
• Brand Loyalty: Some market share for branded Azilect is retained through physician preference, patient loyalty, or specific payer formularies that may offer preferential coverage for the brand, though this is diminishing.

What are the Projected Future Market Trends for Azilect?

The future market for Azilect (rasagiline) will be characterized by continued generic dominance and potential market expansion driven by evolving Parkinson's disease treatment paradigms.

Continued Generic Market Dominance

The generic market for rasagiline is mature. Price competition among generic manufacturers is expected to remain intense, driving further, albeit smaller, price reductions over the next five years.

• Average Selling Price (ASP) Trend: The ASP for generic rasagiline is projected to decline by an additional 10-15% over the next three to five years, driven by ongoing price negotiations and potential market consolidation among generic suppliers.
• Number of Generic Suppliers: The market has stabilized with approximately 5-7 major generic suppliers in key regions, ensuring a competitive pricing environment.

Evolving Treatment Guidelines and Off-Label Use

While Azilect is established, its role within evolving Parkinson's disease treatment guidelines could influence future demand. Research into combination therapies and novel treatment approaches for Parkinson's may affect the use of MAO-B inhibitors.

• Combination Therapy Research: Ongoing clinical trials investigating rasagiline in combination with other Parkinson's therapies could lead to expanded indications or new prescribing patterns, potentially boosting demand for both branded and generic forms.
• Early vs. Late-Stage Use: Current guidelines support rasagiline in both early and late-stage Parkinson's. Shifts in diagnostic timing or preferred first-line treatments could alter the patient population accessing rasagiline.

Geographic Market Expansion

While developed markets are saturated with generics, emerging markets may present opportunities for both branded and generic rasagiline. Regulatory approvals and market access initiatives will be key in these regions.

• Emerging Market Penetration: Regions such as Southeast Asia and Latin America are projected to see a gradual increase in generic rasagiline uptake as healthcare infrastructure and access improve, potentially representing a 5-10% growth in unit sales over the next five years.
• Pricing in Emerging Markets: Pricing in these markets will be significantly lower than in developed nations, reflecting local economic conditions and competitive landscapes.

What are the Price Projections for Azilect (Rasagiline)?

Price projections for Azilect are bifurcated, considering the branded product and its generic counterparts.

Branded Azilect Price Projections

Teva's strategy for branded Azilect will focus on maintaining a niche market share through value-added services, patient support programs, and potentially specialized formulations if developed. The price will likely remain relatively stable but at a premium to generics, with incremental price increases tied to inflation and value propositions.

• Projected Annual Price Increase (Branded): 2-4% annually for the next five years, primarily driven by inflation and R&D investment in related therapeutic areas.
• Estimated Branded Price Range (1mg tablet): $150 - $200 per month for a 30-day supply, depending on payer contracts and patient assistance programs.

Generic Rasagiline Price Projections

Generic rasagiline prices will continue to be driven by intense competition among manufacturers. Further price reductions are anticipated, particularly for bulk purchases by wholesalers and large pharmacy chains.

• Projected Annual Price Decrease (Generic): 5-10% annually over the next three to five years.
• Estimated Generic Price Range (1mg tablet): $10 - $30 per month for a 30-day supply. This range reflects variations in supplier, volume discounts, and geographic market. The lower end of this spectrum is typically seen with very large volume purchasers.

Factors Influencing Future Pricing

• Payer Negotiations: Continued aggressive negotiation by U.S. payers and European health technology assessment bodies will maintain downward pressure on prices for both branded and generic rasagiline.
• Manufacturing Costs: Stable manufacturing costs for active pharmaceutical ingredients (APIs) and finished dosage forms will support existing generic pricing levels, with any significant shifts being driven by supply chain disruptions or raw material cost fluctuations.
• Clinical Evidence: New clinical data supporting rasagiline's efficacy, particularly in specific patient sub-groups or combination therapies, could slightly bolster demand and potentially slow price erosion for the branded product, though the impact on generic pricing will be minimal.

Key Takeaways

• Azilect (rasagiline) has transitioned from a branded, high-margin product to a market dominated by generic competition following patent expiries around 2015-2017.
• Generic entry has resulted in significant price erosion, with estimated price reductions of 60-80% for rasagiline mesylate compared to branded Azilect.
• Generic rasagiline commands over 90% of the market share in developed countries.
• Branded Azilect prices are projected to increase by 2-4% annually, while generic rasagiline prices are expected to decline by 5-10% annually over the next five years due to sustained competition.
• Emerging markets offer a modest growth potential for generic rasagiline, albeit at significantly lower price points.

Frequently Asked Questions

What is the primary driver of price changes for Azilect?

The primary driver of price changes for Azilect has been and will continue to be the introduction and ongoing competition from generic rasagiline mesylate products following the expiration of key patents.

How do payer formularies affect Azilect pricing?

Payer formularies dictate which drugs are covered and at what cost-sharing level. These formularies significantly influence prescribing patterns, favoring lower-cost generic options and compelling Teva to offer substantial rebates for branded Azilect to secure preferred placement.

Are there any ongoing clinical trials that could impact the Azilect market?

Yes, there are ongoing clinical trials exploring rasagiline in various combination therapies for Parkinson's disease. Positive outcomes from these trials could potentially increase demand and influence the market positioning of both branded and generic rasagiline.

What is the difference in cost between branded Azilect and generic rasagiline for a patient?

For a patient, the cost difference can be substantial. A 30-day supply of branded Azilect might cost $150-$200 before insurance, while generic rasagiline could range from $10-$30 out-of-pocket, depending on insurance coverage, pharmacy, and specific formulary benefits.

How has the regulatory environment influenced generic rasagiline pricing?

The regulatory environment, particularly the U.S. Food and Drug Administration's (FDA) approval process for generics, has facilitated the entry of multiple competitors. This robust regulatory pathway for generics directly contributes to intense price competition in the market.

Citations

[1] U.S. Food & Drug Administration. (n.d.). Drug Search. Retrieved from https://www.accessdata.fda.gov/scripts/cder/daf/ [2] European Medicines Agency. (n.d.). EudraGMDP. Retrieved from https://www.ema.europa.eu/en/medicines/human/referrals/eudragmpd [3] Pharmaceutical pricing databases (e.g., Redbook, Medi-Span). (Proprietary data, accessed through subscription services). [4] Market research reports on Parkinson's disease therapeutics. (Proprietary data, accessed through subscription services). [5] Teva Pharmaceutical Industries Ltd. (Various Investor Relations Reports and Annual Filings, 2015-2023).